Join the 'Tamoxifen' group to help and get support from people like you.

Tamoxifen Blog

Breast Cancer Drug Aromasin May Be Option for Some Premenopausal Women

Posted 19 days ago by Drugs.com

WEDNESDAY, July 9, 2014 – The drug exemestane worked slightly better than the drug tamoxifen at preventing a recurrence of breast cancer in certain premenopausal women, according to a new study. Almost 93 percent of women on exemestane (Aromasin) remained free of breast cancer after five years, compared to about 89 percent of the women on tamoxifen. That's according to the study of nearly 4,700 women with breast cancer who all had their ovarian function suppressed. However, the researchers found no differences in overall survival between the two drugs. And both drugs came with significant side effects. For Aromasin, those side effects included osteoporosis, vaginal dryness and decreased sex drive, among others. For tamoxifen, side effects included blood clots, hot flashes and urinary incontinence, according to the study. The study is published in the July 10 issue of the New England ... Read more

Related support groups: Breast Cancer, Tamoxifen, Aromasin, Exemestane, Nolvadex, Tamoxifen Hexal, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Emblon, Soltamox

Newer Anti-Estrogen Treatment May Benefit Younger Breast Cancer Survivors

Posted 2 Jun 2014 by Drugs.com

SUNDAY, June 1, 2014 – A new type of anti-estrogen drug appears to work better than the estrogen-blocking drug tamoxifen in preventing recurrences of breast cancer in certain women, a new study reports. Exemestane (Aromasin), which belongs to a class of drugs called aromatase inhibitors, reduced the relative risk of breast cancer recurrence by nearly a third compared to tamoxifen. But, for exemestane to work in premenopausal women, the drug can only be given when ovarian function is being suppressed. "For years, tamoxifen has been the standard hormone therapy for preventing breast cancer recurrences in young women with hormone-sensitive disease. These results confirm that exemestane with ovarian function suppression constitutes a valid alternative," study lead author Dr. Olivia Pagani, clinical director of the Breast Unit at the Oncology Institute of Southern Switzerland in Bellinzona, ... Read more

Related support groups: Breast Cancer, Tamoxifen, Aromasin, Exemestane, Nolvadex, Tamoxifen Hexal, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Emblon, Soltamox

New Guidelines Recommend Longer Tamoxifen Treatment

Posted 27 May 2014 by Drugs.com

TUESDAY, May 27, 2014 – The hormone-blocking medication tamoxifen should be given for as long as 10 years following treatment of certain types of breast cancer, according to updated guidelines from the American Society of Clinical Oncology (ASCO). "Tamoxifen taken for five years has been the standard . . . but we now have evidence to recommend up to 10 years of tamoxifen for women with hormone receptor-positive breast cancer," guideline update panel co-chair Dr. Harold Burstein said in an ASCO news release. The new guidelines include women with hormone receptor-positive breast cancers between stage 1 and stage 3. Hormone receptor-positive breast cancer is a type of cancer that is fueled by certain hormones, often estrogen. Hormone receptor-positive breast cancer is the most common type of breast cancer worldwide, according to the ASCO news release. Tamoxifen blocks the ability of ... Read more

Related support groups: Breast Cancer, Tamoxifen, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Tamoxifen's Mental Side Effects Are Real, Study Shows

Posted 17 Sep 2013 by Drugs.com

TUESDAY, Sept. 17 – Some women who take tamoxifen to treat or prevent breast cancer report experiencing a mental fogginess while on the drug, and researchers have now confirmed that there's a biological basis for those symptoms. The researchers were able to isolate the cells in the human brain and nervous system that are harmed by tamoxifen therapy. And, in a second phase of the study conducted with mice, they were also able to find a different drug that could protect healthy cells from tamoxifen toxicity while offering no protection to cancer cells. "Patients aren't always taken seriously when they report these mental side effects, but now we can say this is an organic syndrome to which we have to pay attention," said Mark Noble, senior study author. "And, now we know there are paths to protection. This is not a hopeless situation," added Noble, a professor of biomedical genetics, and ... Read more

Related support groups: Breast Cancer, Tamoxifen, Breast Cancer, Prevention, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Women at High Breast Cancer Risk Should Consider Preventive Drugs: Experts

Posted 9 Jul 2013 by Drugs.com

TUESDAY, July 9 – Women at high risk of breast cancer should discuss with their doctors the use of so-called chemopreventive drugs to reduce that risk, according to a new practice guideline issued by the American Society of Clinical Oncology (ASCO). The new guideline updates the previous one, issued in 2009, said Dr. Kala Visvanathan, director of the clinical cancer genetics and prevention service at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, who co-chaired the guidelines panel. "It's a stronger recommendation for discussion of these agents," she said, explaining that the previous guideline suggested the discussion. The new guideline also adds an additional drug option for breast cancer risk reduction. The guideline was published online July 8 in the Journal of Clinical Oncology. The key points include a recommendation to discuss the use of tamoxifen (Nolvadex, ... Read more

Related support groups: Breast Cancer, Tamoxifen, Evista, Aromasin, Exemestane, Breast Cancer, Prevention, Raloxifene, Nolvadex, Tamoxifen Hexal, Tamofen, Tamosin, Soltamox, Tamone, Emblon, Tamoxen, Genox, Nolvadex D

Which Women Might Benefit From Drugs to Prevent Breast Cancer?

Posted 13 Jun 2013 by Drugs.com

THURSDAY, June 13 – Newly identified genetic variations may help predict which women will respond to breast cancer prevention therapy, a new study suggests. By determining who would and would not receive possible benefit from two preventive drugs, women who aren't likely to respond could be spared the treatment and its side effects, the study authors noted. Researchers examined data on women enrolled in two large breast cancer prevention trials, including 592 women who had developed cancer along with 1,171 similar women who did not. The investigators found that women with a favorable genetic variation (called a "single nucleotide polymorphism" or SNP) in the gene ZNF423 and another near the gene CTSO were more likely to respond to prevention therapy with tamoxifen and raloxifene. Women with unfavorable variations of these SNPs may not benefit from prevention therapy and have a ... Read more

Related support groups: Breast Cancer, Tamoxifen, Evista, Breast Cancer, Prevention, Raloxifene, Nolvadex, Tamoxifen Hexal, Tamone, Emblon, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Soltamox

Doubling Time on Tamoxifen Cuts Odds for Breast Cancer's Return: Study

Posted 3 Jun 2013 by Drugs.com

SUNDAY, June 2 – When it comes to using the drug tamoxifen to prevent breast cancer's return, longer may be better for some patients, a new study finds. Women combating estrogen-sensitive breast tumors fared better when treated with 10 years of tamoxifen compared to those given the current standard of five years, researchers found. However, longer tamoxifen regimens were associated with a greater risk for side effects from the cancer-suppressing drug, such as night sweats, hot flashes, blood clots, strokes and a heightened risk for cancer of the lining of the uterus (endometrial cancer). Still, the investigation found that 10 years of treatment gave patients better protection against the recurrence of estrogen receptor (ER)-positive breast cancers and/or death than did treatments offered for half as long. Assessing the findings in conjunction with the results of another recently ... Read more

Related support groups: Breast Cancer, Tamoxifen, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Drugs Can Cut Breast Cancer Risk for Some, Task Force Finds

Posted 15 Apr 2013 by Drugs.com

MONDAY, April 15 – The drugs tamoxifen and raloxifene (Evista) could reduce the risk of breast cancer among women who are at high risk of developing the disease, a new report confirms. Along with the report, the U.S. Preventive Services Task Force also issued draft recommendations that reflect those findings, which will be published in the April 16 issue of the Annals of Internal Medicine. The task force recommendations state that doctors should talk about the potential benefits and harms of taking drugs to prevent breast cancer, a strategy known as chemoprevention, with patients who are at high risk of developing breast cancer. That guideline is consistent with that of the American College of Obstetricians and Gynecologists and the American Cancer Society, and reflects current clinical practice, the task force said. "We had a nice set of well-done, large [studies], so we have a lot of ... Read more

Related support groups: Tamoxifen, Evista, Breast Cancer, Prevention, Raloxifene, Nolvadex, Tamoxifen Hexal, Tamone, Emblon, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Soltamox

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Methotrexate, Depo-Provera, Lupron, Accutane, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Gleevec, Fluorouracil, Claravis, Rituxan, Tretinoin, Zoladex, Votrient, Tarceva, Avastin

Genes Linked to Effectiveness of Tamoxifen for Breast Cancer

Posted 28 Dec 2012 by Drugs.com

FRIDAY, Dec. 28 For breast cancer patients prescribed tamoxifen to treat their disease, genetic traits affecting an enzyme in the liver are major players in determining the impact of the hormone therapy, new research suggests. There's been debate in the scientific world for years over the role of genetic differences in the enzyme, known as CYP2D6. An estimated 5 percent to 7 percent of European and North American women have a trait that prevents the enzyme from working properly. "Our findings confirm that, in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death," Dr. Matthew Goetz, a Mayo Clinic oncologist and lead author of the study that reported the findings, said in a Mayo Clinic news release. The researchers tracked two groups of women: postmenopausal women with primary estrogen receptor-positive breast cancer ... Read more

Related support groups: Breast Cancer, Tamoxifen, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

10 Years of Tamoxifen Better Than 5: Study

Posted 5 Dec 2012 by Drugs.com

WEDNESDAY, Dec. 5 --Taking the breast cancer drug tamoxifen for a decade, instead of the standard five years, further reduces the long-term chances of recurrence and risk of dying from the disease, new British research suggests. The increase in benefit is especially noticeable after the 10th year, said study author Richard Peto, a professor of medical statistics and epidemiology at the University of Oxford. Tamoxifen is widely used for treating estrogen receptor or ER-positive breast cancer in women who are pre-menopausal. ER-positive cancers need estrogen to grow, and the drug blocks the activity of estrogen in the breast. Currently, tamoxifen is usually given daily for five years after a cancer is treated. Doctors have known that five years is more effective than two, and that it reduces the rate of death from breast cancer by about a third in comparison to not taking it, and that it ... Read more

Related support groups: Breast Cancer, Tamoxifen, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Breast Cancer Drug Might Help Men on Prostate Cancer Therapy

Posted 28 Aug 2012 by Drugs.com

TUESDAY, Aug. 28 – The breast cancer drug tamoxifen may reduce some of the side effects caused by hormone therapy for prostate cancer, according to a new study. Androgen-suppression therapy is often used to slow the progression of advanced prostate cancer. But these drugs, which block testosterone activity, can cause side effects such as breast enlargement and pain that may stop men from using this treatment. German researchers examined the results of four independent clinical trials that examined the use of tamoxifen to manage these side effects in prostate cancer patients undergoing androgen-suppression therapy. The study found that tamoxifen reduced the risk of breast enlargement and breast pain in men at three, six, nine and 12 months of treatment compared to men who did not take tamoxifen. Overall, tamoxifen was more successful in reducing breast symptoms than radiation therapy or ... Read more

Related support groups: Prostate Cancer, Tamoxifen, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Risk of Death From Certain Breast Cancers May Rise With Age

Posted 7 Feb 2012 by Drugs.com

TUESDAY, Feb. 7 – The risk of dying from a hormone receptor-positive breast cancer increases with age, according to new research. And one reason might be that older women with breast cancer are undertreated compared to their younger peers. For women between the ages of 65 and 74, the risk of dying from breast cancer was 25 percent higher than for women under 65. For those 75 and older, the risk of death was 63 percent higher than for women under 65, according to the new study. "This study showed that among postmenopausal, non-metastatic, breast cancer patients, elderly patients have a higher risk of dying from breast cancer than younger patients," said study author Dr. Cornelis van de Velde, a professor of surgery at Leiden University Medical Center in the Netherlands and president of the European Cancer Organization. Results of the study are published in the Feb. 8 issue of the ... Read more

Related support groups: Breast Cancer, Tamoxifen, Aromasin, Exemestane, Nolvadex, Tamoxifen Hexal, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Emblon, Soltamox

Side Effects May Spur Men to Drop Tamoxifen for Breast Cancer

Posted 16 Nov 2011 by Drugs.com

WEDNESDAY, Nov. 16 – One in five male breast cancer patients stops taking the drug tamoxifen early due to side effects caused by the medicine and may be at increased risk for cancer recurrence, new research suggests. Tamoxifen is the standard of care for the hormone treatment of male breast cancer patients, according to the authors of a new report published in the Nov. 16 issue of the Annals of Oncology. In the study, researchers at the University of Texas M.D. Anderson Cancer Center in Houston examined the records of 64 male breast cancer patients who received tamoxifen for an average of four years and found that 34 of them (53 percent) experienced one or more tamoxifen-related side effects, such as weight gain and loss of sex drive. Thirteen (20.3 percent) of the patients stopped taking tamoxifen due to the side effects. Nine of the patients died after they discontinued tamoxifen ... Read more

Related support groups: Tamoxifen, Breast Cancer - Male, Nolvadex, Tamoxifen Hexal, Tamosin, Emblon, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen

Femara May Beat Tamoxifen at Preventing Breast Cancer's Return

Posted 24 Oct 2011 by Drugs.com

FRIDAY, Oct. 21 – The breast cancer drug letrozole, marketed as Femara, may be more effective than tamoxifen at preventing the return of breast cancer and improving survival among older women with hormone-sensitive breast cancers, a new study reports. In the study, published online Oct. 21 in The Lancet Oncology, the researchers updated data from an ongoing study of about 8,000 women, which compares the two drugs alone as well as the use of both Femara and tamoxifen sequentially. Femara outperformed tamoxifen in terms of breast cancer recurrence and survival, the study found. Moreover, giving Femara alone to women was more effective than giving it sequentially following tamoxifen. The new study was partially funded by Novartis, the drug company that makes Femara. The hormone estrogen feeds hormone-sensitive cancers, and blocking it may help stave off a recurrence. Femara is part of a ... Read more

Related support groups: Breast Cancer, Tamoxifen, Arimidex, Femara, Anastrozole, Letrozole, Aromasin, Exemestane, Nolvadex, Tamoxifen Hexal, Soltamox, Tamone, Emblon, Tamoxen, Genox, Teslac, Nolvadex D, Tamofen, Tamosin, Testolactone

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Breast Cancer, Prevention, Breast Cancer - Male, Breast Cancer - Palliative, Precocious Puberty, McCune-Albright Syndrome

Related Drug Support Groups

Nolvadex, Tamoxifen Hexal, Tamofen, Tamone, Tamosin, Tamoxen, Emblon, Nolvadex D, Genox, Soltamox

Tamoxifen Patient Information at Drugs.com